Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

CLASSICAL HODGKIN LYMPHOMA Clinical Trial

Official title:

Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02243436
• Other study ID #: BRESHAP-GELTAMO.LH-2013
• Secondary ID: 2014-000835-17
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 11, 2014
• Est. completion date: January 14, 2019

Study information

• Verified date: April 2019
• Source: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to autologous stem cell transplantation.

Description:

Most patients suffering from Hodgkin's lymphoma (HL) can be successfully treated with standard chemo- and/or radiotherapy. However, in patients with refractory disease/relapsing after first line of therapy, conventional-dose chemotherapy regimens induce low remission rates, with long-term disease free survival not higher than 10% of patients.

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard treatment for these patients. This treatment approach results in long-term remissions in approximately 40-50% of relapsed patients, and in up to 25-30% of those with primary refractory disease. The possibility of a cure depends on several prognostic factors, however, in almost all series, the strongest prognostic factor has been the disease status before ASCT. Patients with HL who do not achieve complete remission (CR) after induction chemotherapy and those with unresponsive relapse have a very poor prognosis. Therefore, the choice of a very active pre-transplant salvage chemotherapy regimen is extremely important to improve results after ASCT. In addition, this activity should also be combined with a good stem cell mobilizing potential and low toxicity profiled.

Several pre-transplant salvage regimens for refractory/relapsed HL are currently used with an overall response (OR) and CR rates ranging from 60% to 88% and from 17% to 49%, respectively. No randomized trial exists comparing the effectiveness of these regimens. ESHAP (Etoposide, Solumoderin (methylprednisolone), Ara-C (Cytarabine) and cisplatin) is one of the most commonly used regimens. ESHAP induces an OR and CR of 73% and 41%, respectively, with 5% toxic deaths. In the present study, a combination of ESHAP plus Brentuximab Vedotin (BV) is proposed as pre-transplant therapy with the aim to improve the CR rate before ASCT.

HL is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells. The antibody-drug conjugate BV delivers the highly potent antimicrotubule agent monomethyl auristatin E (MMAE) to CD30-positive malignant cells by binding specifically to CD30 on the cell surface and releasing MMAE inside the cell via lysosomal degradation.

Binding of MMAE to tubulin results in apoptotic death of the CD30 expressing tumor cell.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: January 14, 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

• Histologically confirmed relapsed or refractory classical HL after first line chemotherapy. CD30 has to be positive

• Age 18 to 65 years. Patient >65 years old with ECOG =1 and absence of comorbidities will be included in the study

• ECOG =2

• Karnofsky performance status = 60

• No major organ dysfunction

• Biopsy at HL relapse or when refractoriness disease is diagnosed must be done prior to BV-ESHAP. If biopsy cannot be performed, tumor biopsy at initial diagnosis of HL must be available to be revised

• Absence of prior history of other malignant diseases, except:

Basal cell carcinoma of the skin or uterine "in situ" carcinoma adequately treated Any curable neoplasia adequately treated that has achieved complete response and has remained in such status longer than 3 years

• Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse

• Male patients, even if surgically sterilized, agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse

• Life-expectancy >3 months

• Platelet count =75•109/L (or 20 if due to Bone Marrow [BM] infiltration) absolute neutrophil count =1.5•109/L (or 0.5 if due to BM infiltration), and hemoglobin = 8g/dL

• Total Bilirubin: <1.5 x UNL, unless clearly related to the disease (Gilbert disease will be ruled out from this point)

• AST and ALT: <3 xUNL except liver infiltration

• Serum creatinine: < 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance > 40 mL/minute

• Serum sodium >130 mmol/L

• Voluntary written informed consent

Exclusion Criteria:

• Current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)

• Serious medical or psychiatric illness likely to interfere with participation in this clinical study

• Patients that have been treated previously with anti-CD30 monoclonal antibodies

• Myocardial infarction within 6 months prior to enrollment. Heart failure NYHA Class III-IV, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Recent evidence (within 6 months) of a left-ventricular ejection fraction <50%

• Peripheral neuropathy or neuropathic pain grade = 2

• Known cerebral or meningeal disease, including signs or symptoms of PML

• Symptomatic neurologic disease compromising normal activities of daily living or requiring medication

• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in brentuximab vedotin

• Pregnant women or in breast-feeding period, or adults in childbearing period not using an effective contraception method

• Treatment with any known non-marketed drug substance or experimental therapy within the longer of 5 terminal half-lives or 4 weeks prior to enrollment or currently participating in any other interventional clinical study

• Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment within two weeks prior to first study drug dose

• History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae

• HIV positive

• Significant concurrent, uncontrolled medical condition which may represent a risk for the patient

• Positive serology for HBV

• Positive serology for HCV

Related Conditions & MeSH terms

• CLASSICAL HODGKIN LYMPHOMA
• Hodgkin Disease
• Lymphoma

Intervention

Drug:
• Brentuximab Vedotin
Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
• Etoposide
Intravenose use, 40mg/m2/day, on days 1 to 4
• Soludomerin
Intravenous use, 250mg/day, on days 1 to 4
• Cisplatin
Intravenous use, 25mg/m2/day, on days 1 to 4
• Ara C
Intravenous use, 2g/m2, day 5

Locations

Country	Name	City	State
Spain	Institut Català d'Oncologia, Hospital Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Clinic i Provincial de Barcelona	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Institut Català d'Oncologia, Hospital Duran i Reynals	L'Hospitalet de Llobregat	Barcelona
Spain	Hospital General Universitario Gregorio Marañon	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Universitario Central de Asturias	Oviedo	Asturias
Spain	Hospital Son Espases	Palma	Islas Baleares
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Hospital Universitario de Canarias	Santa Cruz de Tenerife
Spain	Hospital Universitario Virgen del Rocío	Sevilla
Spain	Hospital Clínico de Valencia	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended dose	During phase I, defined as the maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant HL patients.	Day 21 of cycle 1 (3 weeks after start of treatment)
Primary	Global response rate prior to ASCT	During phase II, Global response rate after BV-ESHAP as salvage regimen prior to ASCT.	9 weeks (after start of treatment)
Primary	Complete response	Percentage of patients with complete response rate after BV-ESHAP as salvage regimen prior to ASCT.	9 weeks (after start of treatment)
Secondary	Toxicity according to the CTC criteria	To determine the toxicity of BV-ESHAP regimen	Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Stem cell mobilization capacity	To assess the stem cell mobilization capacity of the BV-ESHAP regimen: determine the expanse and effectiveness of the extraction of stem cells from peripheral blood.	After first or second cycle of treatment
Secondary	Transplant-related mortality (TRM)		Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Overall Survival (OS)	Percentage of patients alive after first dose of treatment through follow-up	Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Progression free survival (PFS)	Percentage of patients without progression of disease	Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Event-Free Survival	Percentage of patients without event	Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Time to HL Progression		Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Disease-Free Survival		Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Response Duration	Length of time between date of evidenced response and progression of disease or death	Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Lymphoma-Specific Survival		Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.
Secondary	Time to Next Treatment		Prior every cycle, 14th day of first three cycles, at week 12, 16, 19, 22, 25, 31. Every 12 weeks for 2 years and then every 24 week up to 5 years.